8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________

FORM 8-K

_________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 27, 2023

_________________________________________________

ViewRay, Inc.

(Exact name of Registrant as Specified in Its Charter)

_________________________________________________

Delaware	001-37725	42-1777485
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1099 18th Street, Suite 3000, Denver, Colorado 80202

(Address of Principal Executive Offices, Zip Code)

Registrant’s Telephone Number, Including Area Code: (440) 703-3210

2 Thermo Fisher Way, Oakwood Village, OH 44146

(Former Name or Former Address, if Changed Since Last Report)

_________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01	VRAY	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

Item 7.01 Regulation FD Disclosure.

On February 27, 2023, ViewRay, Inc. (“ViewRay” or the “Company”) issued a press release announcing its financial results for the fourth quarter and full fiscal year ended December 31, 2022. A copy of the press release as well as the appendix is attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively and is incorporated herein by reference.

The information in this report and the exhibits attached hereto is being furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and pursuant to Items 2.02 and 7.01 of Form 8-K will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release dated February 27, 2023 announcing financial results for the quarter ended and year ended December 31, 2022.
99.2	ViewRay Q4 2022 Earnings Appendix
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	VIEWRAY, INC.
Date: February 27, 2023	By:	/s/ Robert S. McCormack
		Robert S. McCormack
		Chief Legal Officer

EX-99.1

Exhibit 99.1

ViewRay Announces Fourth Quarter and Full Year 2022 Results

DENVER, February 27, 2023 — ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2022.

Full Year 2022 Highlights

•Total revenue of $102.2 million primarily from 16 revenue units including one upgrade, compared to 2021 revenue of approximately $70.1 million, primarily from ten revenue units.

•Received a total of 32 orders for the twelve months ended December 31, 2022, totaling $191.0 million, compared to 28 total orders totaling $158.9 million in 2021.

•Total backlog increased to approximately $380.2 million as of December 31, 2022, compared to approximately $313.4 million as of December 31, 2021.

•Cash and cash equivalents was approximately $142.5 million as of December 31, 2022. Cash usage in 2022 was $91.2 million excluding the term loan net proceeds from the November debt restructuring.

Fourth Quarter 2022 Highlights

•Total revenue for the fourth quarter 2022 was approximately $34.7 million, primarily from five revenue units, compared to approximately $20.4 million, primarily from three revenue units, in the fourth quarter of 2021.

•Received nine new orders for MRIdian systems totaling approximately $56.4 million, compared to seven new orders totaling approximately $40.7 million in the fourth quarter of 2021.

“Our innovation and clinical pipelines, along with increased market awareness efforts, are driving therapy adoption," said Scott Drake, President and CEO. "Over 29,000 patients have been treated to date, it’s clear that when patients know highly-effective, short-course, virtually side-effect-free therapy is available, they will demand it and travel for it. We focus on our mission of “Treating and proving what others can’t” which position us to drive revenue growth, gross margin expansion, and expense leverage again in 2023."

Financial Results

Total revenue for the three months ended December 31, 2022 was $34.7 million compared to $20.4 million for the same period last year. Total revenue for the full year 2022 was $102.2 million compared to $70.1 million for the full year 2021.

Total cost of revenue for the three months ended December 31, 2022 was $30.3 million compared to $20.6 million for the same period last year. Total cost of revenue was $92.2 million for the full year 2022 compared to $69.8 million for the full year 2021.

Total gross profit for the three months ended December 31, 2022 was $4.4 million, compared to a gross loss of $0.2 million for the same period last year. Total gross profit for the full year 2022 was $10.0 million compared to gross profit of $0.3 million for the full year 2021.

Total operating expenses for the three months ended December 31, 2022 were $30.4 million, compared to $29.0 million for the same period last year. Total operating expenses for the full year 2022 were $117.2 million compared to $104.0 million for the full year 2021.

Net loss for the three months ended December 31, 2022 was $27.8 million, or $(0.15) per share, compared to $27.1 million, or $(0.16) per share, for the same period last year. Net loss for the full year 2022 was $107.3 million, or $(0.59) per share, compared to $110.0 million, or $(0.67) per share, for the full year 2021.

Non-GAAP adjusted EBITDA for the three months ended December 31, 2022 was a loss of $18.4 million, compared to a loss of $24.1 million for the same period last year. Non-GAAP adjusted EBITDA for the full year 2022 was a loss of $78.2 million compared to a loss of $73.7 million for the full year 2021. We define adjusted EBITDA as EBITDA (defined as net income before net interest expense, depreciation, and amortization), adjusted for impairment of assets, non-cash equity-based compensation, non-cash changes in warrant liability valuations, and non-recurring costs. Refer to the schedule below for a reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA.

ViewRay had total cash and cash equivalents of $142.5 million at December 31, 2022.

Financial Guidance

For the full year 2023, ViewRay anticipates total revenue will increase 25% to 40% and Adjusted EBITDA to be in the range of $(70 million) to $(80 million). Our definition of adjusted EBITDA is set forth above. Refer to the schedule below for a reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA.

Conference Call and Webcast

ViewRay will hold a conference call to discuss results on Monday, February 27, 2023 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in number is (888) 396-8049 and the confirmation number is 47314692. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars.

After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website, under "Financial Events and Webinars", for 14 days following the call.

Use of Non-GAAP Financial Measures

ViewRay reports its financial results in accordance with generally accepted accounting principles in the United States (“GAAP”) and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, ViewRay uses adjusted EBITDA as a non-GAAP financial measure.

ViewRay has supplemented its GAAP net loss with a non-GAAP measure of adjusted EBITDA. We define adjusted EBITDA as EBITDA (defined as net income before net interest expense, depreciation, and amortization), adjusted for impairment of assets, non-cash equity-based compensation, non-cash changes in warrant liability valuations, and non-recurring costs.

Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. Management uses adjusted EBITDA for both strategic and annual operating planning.

Adjusted EBITDA has important limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are that Adjusted EBITDA:

•does not reflect any charges for the assets being depreciated and amortized that may need to be replaced in the future;

•does not reflect the significant interest expense or the cash requirements necessary to service interest or, if any, principal payments on our debt;

•does not reflect the impact of write-downs of long-lived assets;

•does not reflect the impact of share-based compensation upon our results of operations;

•does not reflect the impact of changes in fair value of our warrant liabilities; and

•does not include certain expenses that are non-recurring, infrequent and unusual in nature.

A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.

About ViewRay®

ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, ViewRay's financial guidance for the full year 2023, anticipated future orders, anticipated future operating and financial performance, treatment results, therapy adoption, innovation, and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue and cash collections, the timing of delivery of ViewRay's products, the timing, length, and severity of the COVID-19 pandemic, including its impacts across our businesses on demand, our operations and global supply chains, disruptions in the supply or changes in costs of raw materials, labor, product components or transportation services, including as a result of inflation, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

VIEWRAY, INC.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share data)

	Three Months Ended December 31,				Year Ended December 31,
	2022		2021		2022		2021
Revenue:
Product	$	28,577	$	15,443	$	79,325	$	51,865
Service	5,958		4,825		22,368		17,779
Distribution rights	157		119		513		475
Total revenue	34,692		20,387		102,206		70,119
Cost of revenue:
Product	24,480		16,208		71,238		51,780
Service	5,805		4,388		20,923		18,004
Total cost of revenue	30,285		20,596		92,161		69,784
Gross profit (loss)	4,407		(209)		10,045		335
Operating expenses:
Research and development	8,050		9,066		32,431		31,849
Selling and marketing	8,725		5,848		30,488		16,044
General and administrative	13,579		14,075		52,437		56,091
Impairment charges	—		—		1,816		—
Total operating expenses	30,354		28,989		117,172		103,984
Loss from operations	(25,947)		(29,198)		(107,127)		(103,649)
Interest income	1,058		4		1,686		13
Interest expense	(2,292)		(1,062)		(5,057)		(4,241)
Other income (expense), net	(635)		3,188		3,168		(2,171)
Loss before provision for income taxes	$	(27,816)	$	(27,068)	$	(107,330)	$	(110,048)
Provision for income taxes	—		—		—		—
Net loss attributable to common stockholders, basic and diluted	$	(27,816)	$	(27,068)	$	(107,330)	$	(110,048)
Net loss per share, basic and diluted	$	(0.15)	$	(0.16)	$	(0.59)	$	(0.67)
Weighted-average common shares used to compute net loss per share attributable to common stockholders, basic and diluted	181,357,469		171,221,797		180,697,230		164,521,064
Gross orders	$	56,400	$	40,700	$	191,015	$	158,850
Backlog	$	380,240	$	313,354	$	380,240	$	313,354

VIEWRAY, INC.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share data)

	December 31,
	2022		2021
ASSETS
Current assets:
Cash and cash equivalents	$	135,960	$	218,348
Accounts receivable, net	41,383		21,659
Inventory, net of allowance of $1,522 and $3,071, respectively	31,303		29,617
Deposits on purchased inventory	7,484		4,778
Deferred cost of revenue	6,715		3,342
Prepaid expenses and other current assets	5,509		5,803
Total current assets	228,354		283,547
Property and equipment, net	19,641		20,242
Restricted cash	6,535		1,460
Intangible assets, net	38		44
Right-of-use assets	5,945		9,661
Other assets	10,884		6,853
TOTAL ASSETS	$	271,397	$	321,807
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	28,300	$	9,199
Accrued liabilities	24,682		26,555
Customer deposits	16,006		20,784
Operating lease liability, current	2,860		2,561
Current portion of long-term debt	—		3,222
Deferred revenue, current portion	24,734		13,920
Total current liabilities	96,582		76,241
Deferred revenue, net of current portion	3,069		4,232
Long-term debt	73,339		54,031
Credit revolver	5,000		—
Warrant liability	4,178		6,795
Operating lease liability, noncurrent	5,205		8,066
Other long-term liabilities	1,782		2,647
TOTAL LIABILITIES	$	189,155	$	152,012
Stockholders’ equity:
Preferred stock, par value $0.01 per share; 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021	—		—
Common stock, par value of $0.01 per share; 300,000,000 shares authorized at December 31, 2022 and 2021; 181,586,944 and 179,206,456 shares issued and outstanding at December 31, 2022 and 2021	1,806		1,782
Additional paid-in capital	924,898		905,145
Accumulated deficit	(844,462)		(737,132)
TOTAL STOCKHOLDERS’ EQUITY	82,242		169,795
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	271,397	$	321,807

VIEWRAY, INC.

Reconciliation of GAAP Net Loss to Adjusted EBITDA

(Unaudited)

(In thousands, except share and per share data)

	Three Months Ended December 31,				Year Ended December 31,
	2022		2021		2022		2021
GAAP net loss	$	(27,816)	$	(27,068)	$	(107,330)	$	(110,048)
Depreciation and amortization	1,144		965		4,922		5,984
Stock-based compensation	5,940		4,286		21,608		23,871
Interest expense	2,292		1,062		5,057		4,241
Interest income	(1,058)		(4)		(1,686)		(13)
Loss (gain) on fair value of warrants (a)	1,055		(3,293)		(2,617)		2,284
Impairment (b)	—		—		1,816		—
Adjusted EBITDA	(18,443)		(24,052)		(78,230)		(73,681)

_________________

(a) consists of non-cash gain/losses on our outstanding warrants.

(b) consists of a one-time non-cash impairment charge on the right-of-use assets and related furniture and fixtures of one of our Mountain View, California office space locations.

VIEWRAY, INC.

Forward-Looking Guidance

Reconciliation of Projected Net Loss to Projected Adjusted EBITDA

(Unaudited)

(In thousands, except share and per share data)

	Twelve Months Ended December 31, 2023
	From		To
GAAP net loss	$	(101,000)	$	(111,000)
Depreciation and amortization (a)	4,500		4,500
Stock-based compensation	20,000		20,000
Interest expense	10,500		10,500
Interest income	(3,000)		(3,000)
Loss (gain) on fair value of warrants (b)	(1,000)		(1,000)
Adjusted EBITDA	(70,000)		(80,000)

_________________

(a) consists of depreciation, primarily on property and equipment as well as amortization of intangibles.

(b) consists of non-cash gain/losses on our outstanding warrants.

Contact:

Investor Relations:

Matt Harrison

Investor Relations

ViewRay, Inc.

1-844-MRIdian (674-3426)

Email: investors@viewray.com

Media Enquiries:

Samantha Pfeil

Marketing Communications

ViewRay, Inc.

Email: media@viewray.com

EX-99.2

Earnings Call – FY 2022 February 27, 2023 Exhibit 99.2

2©2023 ViewRay Technologies, Inc. All rights reserved. Forward-looking statement This appendix contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this appendix that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, ViewRay's financial guidance for the full year 2023, anticipated future orders, anticipated future operating and financial performance, treatment results, therapy adoption, innovation, and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the COVID-19 pandemic, including its impacts across our businesses on demand, our operations and global supply chains, disruptions in the supply or changes in costs of raw materials, labor, product components or transportation services as a result of inflation, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this appendix, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Individual customer and patient results are illustrative only and are not predictive of future results. The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. ViewRay issued a press release and appendix for today’s call. The appendix can be downloaded from the “financial events and webinars” portion of our website at www.investors.viewray.com. The call is being broadcast and webcast live, and a replay will be available for 14 days. Listeners are cautioned that comments made by management during the call may include forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties, and actual results could differ from those projected in any forward-looking statement due to numerous factors. For a description of these risks and uncertainties, please see ViewRay's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other SEC filings. Furthermore, the content of this conference call contains time-sensitive information accurate only as of today, February 27, 2023. ViewRay undertakes no obligation to revise or otherwise update any statements to reflect events or circumstances after the date of this appendix. Medical advice disclaimer: ViewRay is a medical device manufacturer and cannot and does not recommend specific treatment approaches. Individual results may vary. Forward-looking statements and disclaimer

3©2023 ViewRay Technologies, Inc. All rights reserved. Our mission: To treat and prove what others can’t. 566 installed globally 29k9k patients treated > 800 systems in planning or installation ~ Thousands of patients with clinically reported outcomes.

4©2023 ViewRay Technologies, Inc. All rights reserved. What we achieved – financial results FY 2022 FY 2022 FY 2021 Change MRIdian orders 32 28 14% MRIdian backlog $380.2M $313.4M 21% Revenue $102.2M $70.1M 46% Gross Margin 10.0% 0.5% +955 bps

5©2023 ViewRay Technologies, Inc. All rights reserved. FY 2022 Revenue 25 – 40% 46% 2023 guidance FY 2023 Adj. EBITDA FY 2022 $(70) – (80)M $(78)M FY 2023

6©2023 ViewRay Technologies, Inc. All rights reserved. Use of Non-GAAP Financial Measure ViewRay reports its financial results in accordance with generally accepted accounting principles in the United States (“GAAP”) and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, ViewRay uses adjusted EBITDA as a non-GAAP financial measure. ViewRay has supplemented its GAAP net loss with a non-GAAP measure of adjusted EBITDA. We define adjusted EBITDA as EBITDA (defined as net income before net interest expense, depreciation, and amortization), adjusted for impairment of assets, non-cash equity-based compensation, non-cash changes in warrant liability valuations, and non- recurring costs. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. Management uses adjusted EBITDA for both strategic and annual operating planning. Adjusted EBITDA has important limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are that Adjusted EBITDA: • does not reflect any charges for the assets being depreciated and amortized that may need to be replaced in the future; • does not reflect the significant interest expense or the cash requirements necessary to service interest or, if any, principal payments on our debt; • does not reflect the impact of write-downs of long-lived assets; • does not reflect the impact of share-based compensation upon our results of operations; • does not reflect the impact of changes in fair value of our warrant liabilities; and • does not include certain expenses that are non-recurring, infrequent and unusual in nature.

7©2023 ViewRay Technologies, Inc. All rights reserved. ‘22 Adj. EBITDA reconciliation(in $, millions) Q1 2022 Q2 2022 Q3 2022 Q4 2022 2022 total 2021 total Net loss ($25.8) ($27.6) ($26.1) ($27.8) ($107.3) ($110.0) Depreciation and amortization 1.2 1.4 1.1 1.1 4.9 6.0 Stock-based compensation 5.0 5.1 5.5 5.9 21.6 23.9 (Gain)/Loss on fair value of warrants (2.8) (2.1) 1.2 1.1 (2.6) 2.3 Interest expense 1.1 0.2 1.5 2.3 5.1 4.2 Interest income (0.0) (0.1) (0.5) (1.1) (1.7) (0.0) Impairment - 1.8 - - 1.8 - Adjusted EBITDA ($21.3) ($21.3) ($17.3) ($18.4) ($78.2) ($73.7)

VISIBLY BETTER 8

XML

Cover	Feb. 27, 2023
Cover [Abstract]
Entity Central Index Key	0001597313
Amendment Flag	false
Document Type	8-K
Document Period End Date	Feb. 27, 2023
Entity Registrant Name	ViewRay, Inc.
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Incorporation, State or Country Code	DE
Entity File Number	001-37725
Entity Tax Identification Number	42-1777485
Entity Addresses [Line Items]
Entity Address, Address Line One	1099 18th Street, Suite 3000
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80202
Local Phone Number	703-3210
Written Communications	false
Title of 12(b) Security	Common Stock, par value $0.01
Trading Symbol	VRAY
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
City Area Code	440
Former Address
Entity Addresses [Line Items]
Entity Address, Address Line One	2 Thermo Fisher Way
Entity Address, City or Town	Oakwood Village
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	44146